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Abstract
Background and Purpose
Thrombopoietin (TPO), a growth factor primarily involved in thrombopoiesis may also have
a role in the pathophysiology of sepsis. In patients with sepsis, indeed, TPO levels are
markedly increased, with disease severity being the major independent determinant of TPO
concentrations. Moreover, TPO increases and correlates with ex vivo indices of platelet
activation in patients with burn injury upon sepsis development, and may contribute to
depress cardiac contractility in septic shock. Still, the role of TPO in sepsis pathophysiology
remains controversial, given the protective role of TPO in other experimental disease mod-
els, for instance in doxorubicin-induced cardiotoxicity and myocardial ischemia/reperfusion
injury. The aim of our study was to define the contribution of TPO in the development of
organ damage induced by endotoxemia or sepsis, and to investigate the effects of inhibiting
TPO in these conditions.
Methods
We synthesized a chimeric protein able to inhibit TPO, mTPOR-MBP, and studied its effect
in two murine experimental models, acute endotoxemia and cecal ligation and puncture
(CLP) model.
Results
In both models, TPO levels markedly increased, from 289.80±27.87 pg/mL to 465.60±45.92
pg/mL at 3 hours in the LPS model (P<0.01), and from 265.00±26.02 pg/mL to 373.70
±26.20 pg/mL in the CLP model (P<0.05), respectively. Paralleling TPO levels, also plate-
let-monocyte aggregates increased, from 32.86±2.48% to 46.13±1.39% at 3 hours in the
LPS model (P<0.01), and from 43.68±1.69% to 56.52±4.66% in the CLP model (P<0.05).
Blockade of TPO by mTPOR-MBP administration reduced histological damage in target
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organs, namely lung, liver, and gut. In particular, neutrophil infiltration and lung septal thick-
ening were reduced from a score of 1.86±0.34 to 0.60±0.27 (P<0.01) and from 1.43±0.37 to
0.40±0.16 (P<0.05), respectively, in the LPS model at 3 hours, and from a score of 1.75
±0.37 to 0.38±0.18 (P<0.01) and from 1.25±0.31 to 0.13±0.13 (P<0.001), respectively, in
the CLP model. Similarly, the number of hepatic microabscesses was decreased from
14.14±1.41 to 3.64±0.56 in the LPS model at 3 hours (P<0.001), and from 1.71±0.29 to 0.13
±0.13 in the CLP model (P<0.001). Finally, the diameter of intestinal villi decreased from
90.69±3.95 μm to 70.74±3.60 μm in the LPS model at 3 hours (P<0.01), and from 74.29
±4.29 μm to 57.50±1.89 μm in the CLP model (P<0.01). This protective effect was associ-
ated with the blunting of the increase in platelet-monocyte adhesion, and, on the contrary,
with increased platelet-neutrophil aggregates in the circulation, which may be related to
decreased neutrophil sequestration into the inflamed tissues. Conversely, circulating cyto-
kine levels were not significantly changed, in both models, by mTPOR-MBP administration.
Conclusion
Our results demonstrate that TPO participates in the development of organ damage
induced by experimental endotoxemia or polymicrobial sepsis via a mechanism involving
increased platelet-leukocyte adhesion, but not cytokine release, and suggest that blocking
TPOmay be useful in preventing organ damage in patients affected by systemic inflamma-
tory response or sepsis.
Introduction
Thrombopoietin (TPO), a growth factor primarily involved in regulating thrombopoiesis [1,
2], has recently emerged as a humoral mediator potentially implicated in the pathogenesis of
sepsis [3].
TPO is constitutively produced by liver and kidneys, and cleared from the circulation by
platelets upon binding to the TPO receptor c-Mpl, followed by internalization of the bound
ligand [1, 2]. Its best characterized action is to stimulate platelet production by acting on mega-
karyocytic progenitor cells, as well as self-renewal and expansion of hematopoietic stem cells
[4]. TPO also acts on cell types other than hematopoietic progenitors, exerting a variety of
effects. In particular, TPO, although unable per se to induce platelet aggregation, enhances the
response of mature platelets to several agonists [5, 6], and increases platelet-leukocyte adhesion
via P-selectin [7], a phenomenon that has been associated with the development of acute coro-
nary syndromes [8]. Moreover, TPO increases oxygen radical release and induces IL-8 produc-
tion by neutrophils and monocytes [9]. Finally, TPO elicits various effects in other c-Mpl-
expressing cells, including endothelial [10, 11], cardiac [12], and neuronal cells [13, 14].
Several studies have previously reported that TPO levels are increased after endotoxin infu-
sion and in patients with sepsis [3], especially those with severe sepsis and septic shock [15].
TPO also increases in patients with burn injury upon sepsis development, and correlates with
ex vivo indices of platelet activation, namely platelet P-selectin expression and increased plate-
let-monocyte adhesion [16], suggesting that TPO, by favoring platelet activation, may contrib-
ute to trigger multi-organ damage in these diseases [3]. Finally, TPO may depress cardiac
contractility in septic shock, since it inhibits adrenergic receptor signal transduction in myocar-
diocytes, and cooperates with TNF-α and IL-1β to the cardio-depressant activity exerted in
vitro by serum of septic shock patients [12]. Similar results, indicating TPO as a mediator of
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organ damage, have also been reported in experimental models of acute lung injury [17] and
acute pancreatitis [18]. However, other studies rather support a protective effect of TPO, for
instance against cardiotoxicity induced by doxorubicin [19] and myocardial ischemia/reperfu-
sion injury [20].
In this study, we aimed to define the role of TPO in the development of organ damage
induced by experimental endotoxemia or polymicrobial sepsis, and to investigate the effects of
inhibiting TPO in these conditions. To this end, we generated and characterized for its inhibit-
ing activity against TPO a soluble recombinant chimeric protein, mTPOR-MBP, composed of
the extracellular portion of mouse TPO receptor mTPOR/cMpl fused to the maltose-binding
protein (MBP) in order to increase its solubility. We then studied whether TPO inhibition by
mTPOR-MBP may reduce organ damage in two widely used experimental models, one mim-
icking a systemic inflammatory response syndrome, induced by i.p. injection of lipopolysac-
charides (LPS), the other a model of abdominal infection leading to polymicrobial sepsis,
represented by the cecal ligation and puncture (CLP) model.
Materials and Methods
Synthesis of mTPOR-MBP
We generated mTPOR-MBP by fusing the extracellular portion of mouse TPO receptor
mTPOR/c-Mpl to maltose-binding protein (MBP). The DNA fragment encoding murine c-
Mpl-extracellular domain (26–491) was amplified by PCR through high-fidelity DNA poly-
merase (Stratagene, La Jolla, CA), using 300 ng of murine c-Mpl cDNA (K.K. Dnaform,
Ibarak–Japan) as a template. The following primers were used: Forward 5’CCGGAATTCATG
AGCCAAGATGTCTTCTTGCTGGCCT3’; Reverse 5’TGCTCTAGATTACAGGAGCAGAG
CAGTCAC3’, carrying, at the 5’-end, the sequence for EcoRI and XbaI restriction enzymes,
respectively. The amplification product was first digested with EcoRI and XbaI and purified on
agarose gel. The 1425 bp PCR product was then sub-cloned into the expression vector pMal-c2
digested with EcoRI and XbaI (New England Biolabs, Ipswich, MA), downstream and in frame
with themalE gene encoding MBP. Escherichia coli strain BL21(DE3)pLysS cells (Biocompare,
Inc., South San Francisco, CA) was transformed with the vector. Protein expression was
induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 h at 37°C. Thereaf-
ter, cells were collected by centrifugation, frozen at -20°C, then thawed at 37°C, and lysed by
sonication. The soluble fraction containing mTPOR-MBP fusion protein was loaded on a pre-
packed amylose affinity column (New England Biolabs), and elution was performed with the
same buffer supplemented with 10 mMmaltose. mTPOR-MBP was finally dialysed against
phosphate-buffered saline (PBS) and stored at -70°C.
Protein was analysed by SDS-PAGE on 8% polyacrylamide gel under reducing conditions,
and transferred onto nitrocellulose. The membrane was blocked with 5% BSA in Tris-buffered
solution containing Tween-20 (TBS-T) overnight at 4°C, followed by incubation with either anti-
murine c-Mpl monoclonal antibody (R&D Systems Inc., Minneapolis, MN), or anti-MBP rabbit
polyclonal serum. Blots were probed with peroxidase-conjugated sheep anti-mouse (Amersham,
Buckinghamshire, UK), or goat anti-rabbit (Pierce, Rockford, IL) antibodies, as appropriate, and
developed with chemiluminescence reagents (PerkinElmer LAS, Boston, MA).
Characterization of mTPOR-MBP
Binding specificity of mTPOR-MBP with TPO was analysed by dot-blot as previously
described [21]. Briefly, recombinant (r) TPO (R&D Systems Inc.) was diluted in PBS buffer
(pH 7.4) at a concentration ranging from 3.12 μg/ml to 25 μg/ml. TNF-α and IL-1β (25 μg/ml,
Sigma-Aldrich, St Louis, MO) were used as controls. 5 μl of each sample were spotted onto a
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nitrocellulose membrane, then blocked with 5% BSA in TBS-T buffer for 1 hour. The mem-
brane was incubated with the mTPOR-MBP (0.5 μg/ml) overnight at 4°C, and subsequently
with anti-murine c-Mpl/TPOR monoclonal antibody for 2 hours at room temperature. Blots
were probed with peroxidase-conjugated sheep anti-mouse antibody and developed with
chemiluminescence reagents.
The ability of mTPOR-MBP to block TPO biological activity in vitro was tested by using a
short-term proliferative assay on the megakaryoblast cell line M-07 [22] and platelet aggrega-
tion experiments in platelet-rich plasma (PRP) [5].
For the proliferative assay, 2x105 M-07 cells were plated in a 96-wells microplate and stimu-
lated with rTPO (50–1000 pg/ml), in the presence or absence of mTPOR-MBP (1–20 μg/ml)
for 48 hours. Afterwards each well was pulsed with 1 μC of tritiated thymidine (Amersham)
allowing incorporation for 16 hours. Cells were then harvested, and thymidine incorporation
was determined in a scintillation counter after addition to each vial of 1mL of scintillation
liquid.
For platelet aggregation experiments, blood was collected by clean venipuncture using a
19-gauge butterfly infusion set, without venous stasis, from healthy adult donors, who had not
taken any medications for at least 2 weeks. Nine volumes of blood were withdrawn in 1 vol of
3.8% trisodium citrate. PRP was prepared by centrifugation for 15 minutes at 180g. Platelet
poor plasma (PPP) was obtained by centrifugation at 2,000g for 10 minutes. Platelet aggrega-
tion in PRP was evaluated according to the Born's method [23], at 37°C with constant rate of
stirring at 1,000 rpm in a lumi-aggregometer (Chronolog, Havertown, PA) using PPP as refer-
ence, setting to 0% the light transmission using PRP and to 100% using PPP. The maximal
aggregation was quantified according to the Weiss formula [24]. PRP samples were incubated
with 100 pg/ml rTPO for 5 minutes, before epinephrine (EPI; Helena Laboratories, Beaumont,
TX), as secondary agonist, was added. For each experiment, the concentration of EPI that
induced the minimummeasurable aggregation was determined (0.1–1 μmol/L). The priming
index (PI) was calculated as the response to rTPO and EPI together, divided by the sum of indi-
vidual responses elicited by rTPO and EPI separately. Using this calculation, a PI> 1 indicated
synergism, a PI = 1 indicated additive response, and PI< 1 indicated inhibition [5,16]. In sepa-
rate experiments, rTPO was pre-incubated with the mTPOR-MBP, or purified MBP as control
(2 μg/ml each), for 5 minutes at 37°C; the mixture of rTPO and mTPOR-MBP or purified
MBP was added to PRP, further incubated for 5 minutes at 37°C and stimulated with EPI.
In preliminary experiments, mice were injected i.p. with 40 μg of mTPOR-MBP, and, for
the next 24 hours, the presence of mTPOR-MBP in plasma was checked. Briefly, blood was
drawn by the tail vein, centrifuged at 600g for 10 minutes in order to obtain plasma, and the
presence of mTPOR-MBP was detected by western blot analysis, using the anti-MBP rabbit
polyclonal serum.
Experimental models
Three month-old male C57BL/6 mice were used for all experiments (the exact n/group distri-
butions are specified in the figure legends). Mice were kept together in groups of five per cage,
housed on a 12 h light-dark diurnal cycle with controlled temperature (21°C to 23°C) and pro-
vided with standard rodent diet and water ad libitum.
Acute endotoxemia was induced by i.p. injection with 40 mg/kg of LPS from E. coli 0111:B4
(Sigma-Aldrich) in a volume of 250 μl sterile saline solution [25]. A separate group of animals
received an i.p. injection of 40 μg of mTPOR-MBP in a volume of 200 μl sterile saline solution,
10 minutes after LPS administration. As controls, separate groups of mice received the same
concentration of mTPOR-MBP alone, MBP alone, and/or sterile saline solution.
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To confirm the results obtained with LPS injection, we used a second model of polymicro-
bial sepsis induced by cecal ligation and puncture (CLP) [26]. Mice were anesthetized with tile-
tamine (80 mg/kg), and a midline abdominal incision was performed. The cecum was
mobilized, ligated below the ileo-cecal valve, and punctured twice with a 25-gauge needle. The
abdomen was then closed in two layers, and the mice injected s.c. with 1.0 ml 0.9% saline. A
separate group of animals received an i.p. injection of 40 μg of mTPOR-MBP in a volume of
200 μl sterile saline solution, 30 minutes after surgery was completed. As controls, separate
groups of mice received the same concentration of MBP alone and/or sterile saline solution.
Sham-operated mice were handled in the same manner, except the cecum was neither ligated
nor punctured.
This study was carried out in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes of Health, as well as institu-
tional guidelines and Italian government regulations. The protocol was approved by the Insti-
tutional Review Committee for Animal Care and Use at the University of Turin (Protocol
Number: 0008619-P). All surgery was performed under anesthesia, and all efforts were made
to minimize suffering. In particular, buprenorphine (0.05 mg/kg i.p.) was administered before
surgery as well as 6 hours after surgery to reduce postoperative pain, and animals were
inspected for signs of illness and/or unusual behavior by research staff at least once per day.
Whenever an animal's condition deteriorated (defined by, among other parameters, decreased
activity, and rapid weight gain) followed by the appearance of signs of imminent death (i.e.
inability to maintain upright position/ataxia/tremor and/or agonal breathing) mice were killed
by using deep inhalation anesthesia (isoflurane) followed by an overdose of barbiturate (thio-
pental). The percentage of premature deaths in both models did not exceed 10%.
Sample collection and cell counts
At the indicated times (basal, 3, and 6 hours after LPS injection, and after 18 hours in the CLP
model), mice were anesthetized with tiletamine (80 mg/kg), and blood samples were collected
from the inferior cava vein into tubes containing trisodium citrate (0.11 mol/liter). The exam-
ined time-points have been chosen on the basis of preliminary experiments performed in our
laboratory, and of similar studies already published in the literature [25, 27, 28]. Blood was
used for platelet and white blood cell counting, using an automated counter, for flow cytometry
analysis, and to obtain plasma, after centrifugation at 600g for 10 minutes. Soon after, liver and
small intestine were rapidly dissected and fixed in 4% neutral buffered formalin for histological
analysis. A polyvinyl catheter was then secured in the trachea, and used to instil 4% neutral
buffered formalin into the lungs at a hydrostatic pressure of 30 cmH2O. Portions of the forma-
lin-distended lungs were harvested and used for histological analysis.
Histological analysis
Histological damage was evaluated on H&E-stained 5 μm paraffin sections by an expert pathol-
ogist (P.D.G.) blind to the sample identity. To measure lung injury, neutrophil infiltration and
alveolar-capillary membrane thickening were scored by assigning a subjective value from zero
(absent) to three (extensive) scale. In each tissue sample, five random fields were scored, and
the mean value was calculated.
To evaluate liver injury, the number of leukocyte microabscesses, i.e. discrete neutrophil
infiltrates around the portal veins that derive from neutrophil infiltration within the liver
parenchyma [25], was counted in 10 randomly-selected fields.
Gut injury was evaluated by measuring intestinal villus thickness in 5 randomly-selected
fields.
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TPO and cytokine measurement
TPO levels in plasma were determined by ELISA (R&D Systems Inc.) according to the manu-
facturer’s recommendations, with the exception of a 3-fold plasma dilution.
Cytokine (TNF-α, IL-6, and IL-10) concentrations were measured in plasma samples using
a fluorescent bead–based multiplex immunoassay (Bio-plex1/Luminex1, Luminex Co., Aus-
tin, TX), as previously described [29, 30].
Flow cytometry
Leukocyte-platelet aggregates ex vivo were analyzed by two-colour staining of whole blood
samples. Briefly, blood was collected, diluted 1:1 with Tyrodes’s Hepes-buffered saline (pH
7.4), and incubated 15 minutes at room temperature with a mixture of PE-Cy5-conjugated
anti-mouse-CD45 monoclonal antibody (eBioscience, San Diego, CA), which binds all leuko-
cytes, and FITC-conjugated anti-mouse-CD41 (Serotec, Raleigh, U.S.A.) monoclonal antibody,
which identifies platelets. Cells were then fixed with 1% paraformaldehyde and erythrocytes
were removed by hypotonic lysis. Samples were washed twice with PBS-BSA 0.1% and resus-
pended in 0.5 ml PBS. Samples were analyzed on a EPICS–XL flow cytometer (Beckman Coul-
ter Corp, Hialeah, FL). Total leukocytes were identified by their positive staining with anti-
CD45 in the CD45 versus side scatter dot plot, whereas lymphocyte, neutrophil and monocyte
populations were discriminated by size and granularity in the forward scatter versus side scat-
ter dot plot using a logic gate. The percentage of monocyte-platelet or neutrophil-platelet
aggregates, therefore co-expressing both markers CD45 and CD41 over the total number of
cells counted within the logic gates previously selected was calculated and used as an index of
platelet-monocyte or platelet-neutrophil adhesion.
Analysis of data
Data are expressed as mean ± S.E.M. Comparisons between groups were analyzed by ANOVA
followed by Newman-Keul’s multicomparison test or by Student’s t test, where appropriate.
Relationship between variables was investigated by Spearman rank correlation coefficient.
A P value< 0.05 was considered significant.
All statistics were done with GraphPad Prism 4.00 for Windows (GraphPad Software, La
Jolla, CA, USA).
Results
Synthesis and characterization of mTPOR-MBP
Aiming to block TPO actions in vivo, we designed and synthesized a chimeric protein, mTPOR-
MBP, originated by the fusion of the extracellular portion of mTPOR/c-Mpl and of MBP, used to
enhance its solubility. The soluble form of mTPOR-MBP was purified by affinity chromatography
using an amylose column, and recognized by antibodies directed against MBP and TPOR/c-Mpl
by western blot. mTPOR-MBP showed dose-dependent high-affinity binding for rTPO in dot-
blot assay, whereas it did not recognized TNF-α and IL-1β (Fig 1A). In addition, it reduced the
proliferation induced by rTPO in M-07 cells (Fig 1B) [22], and the priming effect exerted by rTPO
on epinephrine-induced platelet aggregation in PRP (Fig 1, panels C and D) [5, 8]. mTPOR-MBP
inhibitory effect on platelet aggregation was dose-dependent, and reached a plateau at a concentra-
tion of 1.5–2 μg/ml in the presence of 100 pg/ml of rTPO. mTPOR-MBP alone did not induce any
effect neither on M-07 cell proliferation nor on platelet aggregation (not shown). Finally, once-
daily administration was chosen on the basis of the presence of mTPOR-MBP in mouse plasma,
as detected byWestern blot analysis, up to 24 hours after i.p. administration (Fig 1E).
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TPO concentrations increased in experimental endotoxemia and
polymicrobial sepsis
Previous studies have shown that TPO levels are increased after endotoxin infusion and in
patients with sepsis [3, 15]. Here, we analyzed whether TPO levels were also increased in an
acute endotoxemia model and in the CLP model. In acute endotoxemia induced by LPS i.p.
Fig 1. Characterization of the chimeric protein mTPOR-MBP. (A) Dot-Blot analysis of mTPOR-MBP binding specificity. Recombinant(r) TPO, TNF-α and
IL-1βwere spotted onto a nitrocellulose membrane, then incubated with mTPOR-MBP, and revealed with anti-c-Mpl/TPOR antibody, as described in the
Materials and Methods section. Blots are representative of three independent experiments with similar results. (B) Short-term proliferative assay of M-07 cells
stimulated with 50–1000 pg/ml rTPO in the presence (continuous line) or absence (dotted line) of 2 μg/ml mTPOR-MBP. Data represent means ± S.E.M. of at
least 3 separate experiments with similar results. (C-D) Quantification (C) and representative aggregation traces (D) of the priming effect of 0.5 ng/ml rTPO in
the presence or absence of 2 μg/ml mTPOR-MBP on epinephrine (EPI)-induced platelet aggregation in platelet-rich plasma (see Materials and Methods for
experimental details). C indicates pre-incubation with vehicle alone (phosphate-buffered saline-PBS). The priming index (PI) reported in panel C was
calculated as the response to rTPO and EPI together, divided by the sum of individual responses elicited by rTPO and EPI separately, as detailed in the
Materials and Methods section. Light transmission changes (panel D) are recorded as an expression of platelet aggregation after agonist addition, and
expressed as percent of maximal value (set to 100% using PPP as reference). Data represent means ± S.E.M. of at least 3 separate experiments with similar
results. * P < 0.05; ** P < 0.01; *** P < 0.001. (E) Presence of mTPOR-MBP in the circulation up to 24 hours after i.p injection, as detected by western blot
analysis (see Materials and Methods for details).
doi:10.1371/journal.pone.0151088.g001
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injection, TPO concentrations increased at 3 hours from LPS administration, both in compari-
son to basal levels, and to those measured in mice injected with saline, and decreased at 6 hours
to concentrations lower than those measured at time 0 and after 3 hours (Fig 2A). Also in the
CLP model, TPO levels were significantly increased in septic mice compared to those measured
in sham-operated mice (Fig 2B).
mTPOR-MBP reduces organ damage in experimental endotoxemia and
polymicrobial sepsis
It is known that sepsis mortality is strictly related to the development of injury and failure in
target organs [31]. In both models investigated, the induction of systemic inflammation or sep-
sis was associated with the development of severe histological lesions in the target organs,
which were significantly reduced by mTPOR-MBP administration.
The effect of mTPOR-MBP on the development of organ damage induced by LPS adminis-
tration was evaluated at 3 and 6 hours (Figs 3 and 4). Lung injury, evaluated by measuring neu-
trophil infiltration and alveolar septal thickening, was significantly reduced by mTPOR-MBP
at both time-points (Fig 3).
Moreover, mTPOR-MBP reduced the number of hepatic micro-abscesses around the centro-
lobular veins, consequent to massive infiltration of inflammatory cells into the hepatic paren-
chyma, at both 3 and 6 hours from LPS injection (Fig 4, panels A and B). Finally, mTPOR-MBP
prevented the development of intestinal injury, which led to increased diameter of villi, secondary
to leukocyte recruitment and edema, at both time-points (Fig 4, panel C and D).
Also in the CLP model, mTPOR-MBP significantly reduced the severity of tissue injury
induced in lung, liver and gut (Figs 5 and 6).
mTPOR-MBP alone did not show any effect on lung, liver and gut histology in both models
(not shown).
mTPOR-MBP does not affect cytokine release in experimental
endotoxemia and polymicrobial sepsis
In severe sepsis pathophysiology, intense pro-inflammatory reactions, which includes the
secretion and release of several cytokines in blood, are usually associated with the development
Fig 2. Plasma thrombopoietin (TPO) levels in the LPSmodel (Panel A) and in the cecal ligation and puncture (CLP) model (Panel B). TPO
concentrations were measured by ELISA at the indicated time-points in the LPS model and 18 hours after sepsis induction in the CLPmodel. The number of
animals studied per experimental group was as follows: Panel A: Control (C) = 13; LPS 3h = 11; LPS 6h = 6. Panel B: Sham-operated mice = 5; CLP = 6. *
P < 0.05; ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0151088.g002
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of collateral tissue damage and consequent organ failure [31]. As expected, the induction of
systemic inflammation or sepsis was associated with a relevant increase in circulating cytokine
concentrations in both models studied (Fig 7). Plasma levels of TNF-α, IL-6, and IL-10 were
strongly increased after 3 and 6 hours from LPS administration, as well as after sepsis induction
in the CLP model, in comparison to those measured in saline-injected or sham-operated mice
Fig 3. Effect of mTPOR-MBP on the development of lung damage in the LPSmodel. (A) Representative
micrographs of lung histology in LPS-injected mice untreated (upper panel) or treated (lower panel) with
mTPOR-MBP at the indicated time-points (see Materials and Methods for experimental details). Original
magnification, X200. Black bars, 50 μm. (B) Quantification of neutrophil infiltration within lung septa after LPS
administration, in mice treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials
and Methods for methodological details). (C) Quantification of lung septal thickening after LPS administration,
in mice treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for
methodological details). The number of animals studied per experimental group was as follows: Control (C) =
6; mTPOR-MBP alone = 5; LPS 3h = 7; LPS 3h + mTPOR-MBP = 10; LPS 6h = 6; LPS 6h
+ mTPOR-MBP = 5. * P < 0.05; ** P < 0.01.
doi:10.1371/journal.pone.0151088.g003
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Fig 4. Effect of mTPOR-MBP on the development of liver and intestinal damage in the LPSmodel. (A) Representative micrographs of liver histology in
LPS-injected mice untreated (upper panel) or treated (lower panel) with mTPOR-MBP at the indicated time-points (see Materials and Methods for
experimental details). Original magnification, X200. Black bars, 50 μm. (B) Quantification of hepatic micro-abscesses after LPS administration, in mice
treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological details). (C) Representative micrographs
of gut histology in LPS-injected mice untreated (upper panel) or treated (lower panel) with mTPOR-MBP at the indicated time-points (see Materials and
Methods for experimental details). Original magnification, X200. Black bars, 50 μm. (D) Quantification of intestinal villus diameter after LPS administration, in
mice treated (dashed columns) or not (black columns) with mTPOR-MBP(see Materials and Methods for methodological details). The number of animals
studied per experimental group was as follows: Control (C) = 6; mTPOR-MBP alone = 5; LPS 3h = 7; LPS 3h + mTPOR-MBP = 10; LPS 6h = 6; LPS 6h
+ mTPOR-MBP = 5. * P < 0.05; ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0151088.g004
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(Fig 7). Quite surprisingly though, mTPOR-MBP did not induce any significant change in
cytokine levels neither in the LPS model at both time-points examined (Fig 7, panels A-C), nor
in the CLP model, although a tendency toward a reduction in TNF-α levels was observed in
this model (Fig 7, panels D-F).
mTPOR-MBP alone did not show any effect on cytokine levels (not shown).
mTPOR-MBPmodulates platelet-leukocyte adhesion in experimental
endotoxemia and polymicrobial sepsis
Sepsis development has been associated with the appearance in the circulation of increased
platelet-monocyte and platelet-neutrophil aggregates, which are believed to have a relevant
role in the progression to the most severe forms of the disease [31]. In particular, platelet-
monocyte adhesion is considered an early and sensitive measure of platelet activation [32],
while platelet-neutrophil interaction has a crucial role in the recruitment of neutrophils to
Fig 5. Effect of mTPOR-MBP on the development of lung damage in the cecal ligation and puncture (CLP) model. (A) Representative micrographs of
lung histology in sham-operated mice and septic mice 18 hours after CLP, treated or not with mTPOR-MBP (see Materials and Methods for experimental
details). Original magnification, X400. Black bars, 50 μm. (B) Quantification of neutrophil infiltration within lung septa in sham-operated mice (white columns)
and septic mice 18 hours after CLP, treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological
details). (C) Quantification of lung septal thickening in sham-operated mice (white columns) and septic mice 18 hours after CLP, treated (dashed columns) or
not (black columns) with mTPOR-MBP (see Materials and Methods for methodological details). The number of animals studied per experimental group was
as follows: Sham-operated mice = 10; CLP = 8; CLP + mTPOR-MBP = 8. ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0151088.g005
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inflamed tissues and in the development of target organ injury [33]. Therefore, we studied the
effects of mTPOR-MBP administration on platelet-leukocyte adhesion in both experimental
models.
In the LPS model, both platelet-monocyte and platelet neutrophil aggregates increased at 3
hours, and decreased to levels lower than basal values at 6 hours from LPS injection (Fig 8, pan-
els A-C). The temporal trend of platelet-leukocyte adhesion closely paralleled that of TPO
release in the circulation of LPS-treated mice. Furthermore, we found a significant correlation
Fig 6. Effect of mTPOR-MBP on the development of liver and intestinal damage in the cecal ligation and puncture (CLP) model. (A) Representative
micrographs of liver histology in sham-operated mice and septic mice 18 hours after CLP, treated or not with mTPOR-MBP (see Materials and Methods for
experimental details). Original magnification, X200. Black bars, 50 μm. (B) Quantification of hepatic micro-abscesses in sham-operated mice (white columns)
and septic mice 18 hours after CLP, treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological
details). (C) Representative micrographs of gut histology in sham-operated mice and septic mice 18 hours after CLP, treated or not with mTPOR-MBP (see
Materials and Methods for experimental details). Original magnification, X200. Black bars, 50 μm. (D) Quantification of intestinal villus diameter in sham-
operated mice (white columns) and septic mice 18 hours after CLP, treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and
Methods for methodological details). The number of animals studied per experimental group was as follows: Sham-operated mice = 10; CLP = 8; CLP
+ mTPOR-MBP = 8. * P < 0.05; ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0151088.g006
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between TPO levels and platelet-monocyte adhesion (r = 0.5185, P<0.05), and between TPO
levels and platelet-neutrophil adhesion (r = 0.6805, P<0.001) measured ex vivo. mTPOR-MBP
administration significantly blunted the increase in both platelet-monocyte and platelet-neu-
trophil adhesion observed at 3 hours from LPS administration (Fig 8, panels B and C). On the
contrary, the percentage of both platelet-monocyte and platelet-neutrophil aggregates were
higher in endotoxemic mice treated than in those untreated with mTPOR-MBP after 6 hours
from LPS injection (Fig 8, panels B and C).
Analogously to what we observed in the LPS model, also in the CLP model platelet-mono-
cyte adhesion was enhanced after sepsis induction in comparison to that measured in sham-
operated mice (Fig 8D), showing a temporal trend similar to that of TPO release in the circula-
tion. However, no correlation was found between TPO and platelet-monocyte adhesion in this
model. Moreover, mTPOR-MBP administration was associated with a significant reduction in
the percentage of platelet-monocyte aggregates, to levels similar to those detected in sham-
operated mice (Fig 8D). On the contrary, platelet neutrophil binding in septic mice did not dif-
fer from the levels observed in sham-operated mice, at least at the time-point examined (Fig
8E), while the administration of mTPOR-MBP was associated with an evident increase in cir-
culating platelet-neutrophil aggregates in septic mice (Fig 8E).
Fig 7. Plasma cytokine levels in the LPSmodel (upper panels) and in the cecal ligation and puncture (CLP) model (lower panels). Cytokine (TNF-α,
IL-6, and IL-10) concentrations were measured in plasma samples (n = 5 per experimental group) at the indicated time-points in the LPSmodel and 18 hours
after sepsis induction in the CLP model using a fluorescent bead–based multiplex immunoassay (Bio-plex1/Luminex1, Luminex Co., Austin, TX), as
previously described [29, 30].
doi:10.1371/journal.pone.0151088.g007
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Fig 8. Effect of mTPOR-MBP on platelet-leukocyte adhesion in LPSmodel and in the cecal ligation and puncture (CLP) model. (A) Representative
flow cytometry analysis of platelet-monocyte (upper lane) and platelet-neutrophil aggregates (lower lane) detected in mice injected with saline (Control) and
in mice injected with LPS treated or not with mTPOR-MBP. The two left panels show an example of monocyte (upper panel) and neutrophil (lower panel)
subpopulations, identified by size and granularity in the forward scatter (FS LIN) versus side scatter (SS LIN) dot plot, using a logic gate, over the total
CD45-positive leukocyte population. The others panels are representative of CD45 versus CD41 dot plots obtained in the different experimental conditions.
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No change in platelet-leukocyte adhesion was detected in mice injected with saline or
mTPOR-MBP alone in both experimental models.
Finally, the induction of systemic inflammation or sepsis was associated with a relevant
decrease in leukocyte and platelet counts in both models, an effect that was neither observed in
mice injected with saline or mTPOR-MBP alone, nor in sham-operated mice (Fig 9). The
administration of mTPOR-MBP did not prevent the drop in leukocyte and platelet count at 3
hours from LPS injection, and had only a modest effect on leukocyte count, which resulted
higher in LPS-treated mice than controls, but not on platelet count, at 6 hours (Fig 9, panels A
and B). No effect on leukocyte and platelet count drop was observed after mTPOR-MBP
administration in the CLP model either (Fig 9, panels C and D).
Discussion
The aim of this study was to define the contribution of TPO in enhancing platelet-leukocyte
adhesion associated with systemic inflammation and sepsis, and to explore the potential thera-
peutic effect of TPO blockade in inhibiting the development of organ damage in an acute endo-
toxemia model, which mimics a systemic inflammatory response syndrome, and in the CLP
model, which is an abdominal infection model that leads to polymicrobial sepsis. Therefore, we
synthesized a chimeric protein, mTPOR-MBP, and characterized it for its ability to inhibit in
vivo the biological activity of TPO. We then tested its effects in these two widely used murine
experimental models.
Until now, the involvement of TPO in the pathogenesis of sepsis and other acute critical dis-
eases has remained controversial. Whereas several observations have suggested, in recent years,
that TPO may be involved in the pathogenesis of sepsis and of other critical diseases, for
instance acute lung injury and acute pancreatitis [3, 12, 15–18], some studies have rather sus-
tained a beneficial effect of TPO administration in preventing organ damage [19, 20]. A first
major finding of our study resides in the observation that mTPOR-MBP, by inhibiting TPO in
vivo, reduced histological damage in target organs (lung, liver, and gut) in both models studied.
This result confirms and further supports the hypothesis that TPO may represent a pathogenic
mediator of organ damage in sepsis and other critical diseases, for instance burn injury [3].
In both experimental models, TPO and cytokine concentrations significantly increased after
the induction of systemic inflammation or sepsis, confirming their resemblance, for this aspect,
to what observed in patients [15, 16]. Furthermore, we observed an increase in platelet-mono-
cyte aggregation in both models, with a temporal trend similar to that of TPO release in the
bloodstream, which could suggest that TPO may be responsible for stimulating platelet activa-
tion and platelet-monocyte aggregation associated with the development of systemic inflam-
mation and sepsis. This conclusion is further supported by the positive correlation we found
between TPO and platelet-leukocyte adhesion in the LPS model. On the contrary, TPO and
platelet-leukocyte adhesion did not correlate in the CLP model, at least at the time-point we
examined. This discrepancy between the two models may be related to the differences in the
model pathophysiology. The CLP model, indeed, closer reproduces the complex
Platelet-monocyte and platelet-neutrophil aggregates were identified, within the logic gates previously selected, as CD45 and CD41 double-positive cells
(see the Materials and Methods section for experimental details). (B-C) Quantification of the percentage of platelet-monocyte (panel B) and platelet-
neutrophil (panel C) aggregates detected ex vivo by flow cytometry at the indicated time-points after LPS administration, in mice treated (dashed columns) or
not (black columns) with mTPOR-MBP. The number of animals studied per experimental group was as follows: Control (C) = 10; mTPOR-MBP alone = 9;
LPS 3h = 8; LPS 3h + mTPOR-MBP = 6; LPS 6h = 5; LPS 6h + mTPOR-MBP = 5. (D-E) Quantification of the percentage of platelet-monocyte (panel D) and
platelet-neutrophil (panel E) aggregates detected ex vivo by flow cytometry in sham-operated mice (white columns) and septic mice 18 hours after CLP,
treated (dashed columns) or not (black columns) with mTPOR-MBP. The number of animals studied per experimental group was as follows: Sham-operated
mice = 5; CLP = 5; CLP + mTPOR-MBP = 5. * P < 0.05; ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0151088.g008
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pathophysiology of human sepsis, associated with the activation of a number of host mediator
systems [34], whereas endotoxemia induced by LPS injection, rather mimics a systemic inflam-
matory response syndrome, usefully allowing to more precisely study the time-course of the
inflammatory events elicited by LPS. Therefore, it may be hypothesized that TPO may be
involved in triggering the early phase of platelet-leukocyte adhesion, which could be later sus-
tained, at least in sepsis, by other mediators.
The administration of mTPOR-MBP inhibited the increase of platelet-monocyte binding
both in the LPS model at three hours and in the CLP model, definitively showing that high
Fig 9. White blood cell (WBC) and platelet counts in LPSmodel and in the cecal ligation and puncture (CLP) model. Panel A and B showWBC and
platelet counts, respectively, measured at the indicated time-points after LPS administration in mice treated (dashed columns) or not (black columns) with
mTPOR-MBP. The number of animals studied per experimental group was as follows: Control (C) = 11; mTPOR-MBP alone = 8; LPS 3h = 11; LPS 3h
+ mTPOR-MBP = 10; LPS 6h = 6; LPS 6h + mTPOR-MBP = 8. Panel C and D showWBC and platelet counts, respectively, measured in sham-operated
mice (white columns) and septic mice 18 hours after CLP, treated (dashed columns) or not (black columns) with mTPOR-MBP. The number of animals
studied per experimental group was as follows: Sham-operated mice = 5; CLP = 11 CLP + mTPOR-MBP = 7. ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0151088.g009
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TPO levels represent a pivotal stimulus of platelet activation and platelet-monocyte aggrega-
tion in these two models. On the contrary, mTPOR-MBP administration was associated with
the persistence of platelet-neutrophil aggregates in the circulation at levels higher than in
untreated mice, both in the LPS model at 6 hours and in the CLP model. Several studies have
previously shown that platelet activation and thrombocytopenia are associated with the devel-
opment of organ dysfunction during sepsis and with increased sepsis severity [35–37]. Fre-
quent abnormalities in platelet count have been, indeed, reported, and sepsis severity correlates
with the decrease in platelet count [35–40]. Furthermore, circulating platelets are activated in
experimental sepsis models, as well as in septic patients [35–37, 41–44], a phenomenon that
can predispose to micro-thrombotic events, which may reduce organ perfusion and participate
in microcirculatory dysfunction [45–50]. In addition, sepsis development has been associated
with increased surface expression of platelet adhesion molecules, and increased circulating
platelet-monocyte aggregates, which are considered not only a sensitive measure of platelet
activation, but also have major pro-inflammatory and pro-thrombotic consequences [32].
Finally, a link between platelet-leukocyte, in particular platelet-neutrophil adhesion, and clini-
cal outcome has been reported in septic patients [33, 42–44]. Platelet-neutrophil aggregates,
which are required for the recruitment of neutrophils to inflamed tissues [33], increase, indeed,
upon sepsis development, but decrease in those patients who develop organ failure and eventu-
ally die [42, 44]. This phenomenon is considered expression of the increased recruitment of
neutrophils to inflamed tissues and peripheral sequestration, which may be implicated in the
development of sepsis-induced multiple organ dysfunction syndrome [33, 42, 44]. Therefore,
the increase of platelet-neutrophil adhesion observed in our study at later time-points after
mTPOR-MBP administration may reflect the inhibition of platelet activation and adhesion to
leukocytes and, consequently, of platelet-neutrophil aggregates to the endothelium, which may
be implicated in the protective effect of TPO blockade on inflammation- or sepsis-induced
organ-damage. These results are in agreement with those of previous experimental studies that
suggest that inhibiting platelet activation may reduce sepsis-related mortality. For instance,
platelet depletion had a protective effect in CLP model [51–53], and the modulation of platelet
activation by using specific anti-P-selectin antibody [53] or drugs that inhibit platelet activa-
tion, such as clopidogrel, was beneficial [54] both in endotoxin shock [54] and polymicrobial
sepsis [55], leading to hypothesize that anti-platelet drugs may represent a potential treatment
in sepsis or acute respiratory distress syndrome [56].
In our study, we observed a dramatic reduction in leukocyte and platelet counts in both
models, which was not prevented by mTPOR-MBP. Therefore, this well-described phenome-
non is not related to TPO activity, but rather to the direct action of LPS on leukocytes, and,
may be, platelets themselves. However, this observation excludes that the decrease in platelet-
leukocyte aggregation we detected with mTPOR-MBP may be caused by the drop in leukocyte
and platelet absolute counts.
Quite surprisingly, mTPOR-MBP was not able to inhibit the increase in plasma concentra-
tions of TNF-α, IL-6 and IL-10 observed in both models, a well-known phenomenon that par-
ticipates in the initiation and progression of organ damage during systemic inflammation and
sepsis [31]. Therefore, our data shows that TPO inhibition by mTPOR-MBP exerts its protec-
tive effect on organ damage primarily by influencing platelet-leukocyte adhesion, while it does
not affect cytokine release. Similar results, i.e. a dissociation between the protective effect on
sepsis-related mortality and cytokine increased production, were previously described, in a
model of endotoxin shock, with the administration of erythropoietin, another hematopoietic
growth factor/cytokine [57]. This observation has interesting implications for our knowledge
of sepsis pathogenesis, since it suggests that the development of sepsis-induced organ damage
and cytokine release may not be necessarily related. However, our experimental data cannot
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exclude that the inhibition by mTPOR-MBP of other TPO actions, for instance the ability to
stimulate the production of oxygen radicals or IL-8 from leukocytes, or to modulate apoptosis
in several cell types [3], may also have had a role in the effects observed in our study. Finally,
another intriguing hypothesis may be evoked to explain the protective effect of TPO blockade
in these experimental models. We have previously shown that high TPO concentrations in
plasma samples from patients with septic shock cooperate with TNF-α and IL-1β in depressing
myocardial contractility [12]. Therefore, we could hypothesize that blocking TPO in vivo by a
selective antagonist as mTPOR-MBP could inhibit the priming effect of TPO on the activity of
other mediators, such as inflammatory cytokines, thus dampening the development of damage
to target organs.
We cannot precisely define the origin of the rise in TPO levels observed in our study after
the induction of acute endotoxemia and polymicrobial sepsis. Platelet mass is considered the
primary regulator of TPO levels [4], and both endotoxemic and septic animals had a profound
thrombocytopenia, together with increased indices of ex vivo platelet activation. Platelets
themselves, which are known to release active TPO upon stimulation [58], could also be a
major source for TPO release. Finally, high TPO levels may derive from increased hepatic syn-
thesis, since IL-6 enhances TPO synthesis from hepatocytes [59]. However, this last possibility
can be excluded in the LPS model, on the basis of the kinetic of TPO appearance in mouse
plasma, too rapid to implicate protein synthesis.
Several limits have to be taken into account in interpreting our results. First, we did nor
evaluate the effect of TPO inhibition on long-term organ protection, neither on survival and
recovery in both models. Therefore, we cannot exclude that the observed effects of
mTPOR-MBP administration are transient, and/or that TPO inhibition has not a significant
impact on disease evolution. Second, we cannot provide a clear demonstration of the mecha-
nistic effect of TPO in the pathophysiology of systemic inflammation or sepsis. Although
intriguing, the link between the observed effects of TPO inhibition on platelet-leukocyte inter-
action and the development of inflammation- or sepsis-associated tissue damage in target
organs still remains not definitely proven by our experiments.
In conclusion, blockade of TPO biological activity significantly reduced the severity of
organ damage in both experimental endotoxemia and polymicrobial sepsis. This protective
effect is associated with the inhibition of the increase in platelet-leukocyte adhesion, but not of
cytokine release, observed during systemic inflammation and sepsis. Our results support the
need to further explore the possibility of inhibiting TPO in the intent to prevent or reduce
organ damage in patients affected by systemic inflammatory response or sepsis.
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